More on DWTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.88 |
|
|||
| Open | $1.88 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.00 | ||||
| Day Low | $1.83 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 53,085 | ||||
- H.C. Wainwright Reiterates Buy Rating on Dogwood Therapeutics, Inc. (DWTX)
- Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
- Form 10-Q Dogwood Therapeutics, For: Jun 30
- Form SCHEDULE 13G/A Dogwood Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
- Form 8-K Dogwood Therapeutics, For: Aug 13
- Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
- Dogwood Therapeutics enrolls 200 patients in Halneuron pain trial
- Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
- Dogwood Therapeutics names Iain Dukes to lead new advisory board
- Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Entities mentioned with DWTX
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Dividend | View Related Stories »
- S3 | View Related Stories »
- Show More...
